These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30027791)

  • 81. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
    de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
    Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
    Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
    Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 87. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
    Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation.
    Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
    Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet.
    Pereira LAL; Meng C; Amoedo MAG; Mendes MTSCPF; Marques MAMP; Frazão JMMD; Weigert ALL
    Nefrologia (Engl Ed); 2023; 43(2):197-203. PubMed ID: 36437202
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
    Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA
    BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
    Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
    PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.
    Imafuku T; Tanaka M; Tokunaga K; Miyamura S; Kato H; Tanaka S; Nakano T; Hirata K; Kadowaki D; Maeda H; Matsushita K; Otagiri M; Komaba H; Fukagawa M; Watanabe H; Maruyama T
    Biol Pharm Bull; 2020; 43(10):1583-1590. PubMed ID: 32999168
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.].
    Hamano N; Fukagawa M
    Clin Calcium; 2017; 27(4):567-572. PubMed ID: 28336834
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.
    Karaboyas A; Muenz D; Hwang Y; Goodman W; Cheng S; Desai P; Fox KM; Robinson BM; Pisoni RL
    Kidney Med; 2022 Jun; 4(6):100475. PubMed ID: 35637925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.